Arctic Bioscience

Equities

ABS

NO0010859580

Pharmaceuticals

Market Closed - Oslo Bors 10:45:00 2024-04-25 am EDT 5-day change 1st Jan Change
9.85 NOK 0.00% Intraday chart for Arctic Bioscience -1.01% -6.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Arctic Bioscience AS, Q4 2023 Earnings Call, Mar 01, 2024
Arctic Bioscience Announces Treatment start for 519 patients in the HeROPA-Study CI
Arctic Bioscience Completes Patient Enlistment for Psoriasis Drug Candidate’s Mid-stage Study MT
Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial CI
Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial CI
Arctic Bioscience AS Provides Revenue Guidance for the Year 2023 CI
Transcript : Arctic Bioscience AS, H1 2023 Earnings Call, Aug 29, 2023
Arctic Bioscience AS Provides Earnings Guidance for the Year 2023 CI
Arctic Bioscience AS Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Arctic Bioscience Establishes Credit Facility of NOK 30 Million CI
Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing CI
Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Arctic Bioscience Secures Approval for Psoriasis Treatment Trial in Norway, Finland, Germany, Poland MT
Arctic Bioscience - The HeROPA phase IIb clinical trial approved in Norway, Finland, Germany and Poland CI
Arctic Bioscience Buys Norwegian Microalgae Producer Arctic Algae MT
Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million. CI
Arctic Bioscience Recruits First Patient For UK Psoriasis Investigational Medication Trial MT
Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK CI
UK Regulators Approve Arctic Bioscience's Clinical Trial Application For Psoriasis Medication MT
Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK CI
Arctic Bioscience as Maintains Earnings Guidance for the Year 2022 CI
Norway's Arctic Bioscience Submits Application To Launch Mid-stage Trial Of Psoriasis Drug MT
Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb CI
Arctic Bioscience Nears Submission of Application to Start Study of Psoriasis Drug MT
Chart Arctic Bioscience
More charts
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
9.85 NOK
Average target price
10 NOK
Spread / Average Target
+1.52%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ABS Stock
  4. News Arctic Bioscience
  5. Arctic Bioscience : to Launch Phase 2 Study for Psoriasis Treatment Drug